• HOME
  •  > 
  • 臨床医学：内科
  •  > 
  • 血液
  •  >  血液検査×総合診療　非血液専門医・ジェネラリストのためのBasic＆Practical血液診療

血液検査×総合診療　非血液専門医・ジェネラリストのためのBasic＆Practical血液診療

出版社： 診断と治療社
著者：
発行日： 2022-03-22
分野： 臨床医学：内科  >  血液
ISBN： 9784787825483
電子書籍版： 2022-03-22 （電子版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,390 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,390 円(税込)

購入する

商品紹介

血液診療全般に通じ，かつジェネラリストである超実力派著者による「非血液専門医」「ジェネラリスト」のための血液診療指南書の決定版！「非血液専門医」「ジェネラリスト」の方に向け，症例ベースで，日常診療の現場で血液疾患をどのように考え，診断し，対応すればいいかといった思考の過程を見える化し，非専門医が対応可能な血液疾患患者に適切に対応するために必要なことのエッセンスを凝縮しました！　これ一冊で，あなたも血液検査を基に診断できる！もう血液疾患は怖くない！

目次

  • Part A　検査所見からのアプローチ

    赤血球系の異常
    1 貧血のBasic & Practice
    1-1　貧血のBasic
    1-2　貧血のPractice
    コラム 温泉の効用

    2 赤血球増加症（多血症）のBasic & Practice
    2-1　赤血球増加症のBasic
    2-2　赤血球増加症のPractice
    コラム 使えるものは何でも使う！①

    白血球系の異常
    1 白血球減少
    1-1　白血球減少のBasic & Practice
    1-2　好中球減少のBasic & Practice
    1-3　リンパ球減少のBasic & Practice
    1-4　その他の白血球分画の減少

    2 白血球増多
    2-1　白血球増多のBasic & Practice
    2-2　好中球増多のBasic & Practice
    2-3　リンパ球増多のBasic & Practice
    2-4　好酸球増多のBasic & Practice
    2-5　その他の白血球分画の増多

    3 異型リンパ球のBasic & Practice
    3-1　異型リンパ球のBasic
    3-2　異型リンパ球のPractice
    コラム 中国4000年の歴史？

    血小板の異常
    1 血小板減少のBasic & Practice
    1-1　血小板減少のBasic
    1-2　血小板減少のPractice
    コラム 使えるものは何でも使う！②

    2 血小板増多のBasic & Practice
    2-1　血小板増多のBasic
    2-2　血小板増多のPractice

    汎血球減少
    1 汎血球減少のBasic & Practice
    1-1　汎血球減少のBasic
    1-2　汎血球減少のPractice

    血清蛋白の異常
    1 血清蛋白の異常のBasic & Practice
    1-1　血清蛋白の異常のBasic
    1-2　血清蛋白の異常のPractice


    Part B　臨床症状からのアプローチ

    出血傾向と凝固傾向
    1 出血傾向のBasic ＆ Practice
    1-1　出血傾向のBasic
    1-2　出血傾向のPractice

    2 凝固傾向のBasic ＆ Practice
    2-1　凝固傾向のBasic
    2-2　凝固傾向のPractice

    リンパ節腫脹と脾腫
    1 リンパ節腫脹のBasic ＆ Practice
    1-1　リンパ節腫脹のBasic
    1-2　リンパ節腫脹のPractice
    コラム こぶとりじいさん

    2 脾腫のBasic ＆ Practice
    2-1　脾腫のBasic
    2-2　脾腫のPractice

    意識障害
    1 意識障害のBasic ＆ Practice
    1-1　意識障害のBasic
    1-2　意識障害のPractice

    発熱
    1 発熱のBasic ＆ Practice
    1-1　発熱のBasic
    1-2　発熱のPractice

    疼痛
    1 疼痛のBasic ＆ Practice
    1-1　疼痛のBasic
    1-2　疼痛のPractice

    浮腫
    1 浮腫のBasic ＆ Practice
    1-1　浮腫のBasic
    1-2　浮腫のPractice


    Part C　健康診断からのアプローチ

    健康診断で見つかった血液異常をどうするか？
    1 健康診断で見つかった血液異常のBasic & Practice
    1-1　健康診断で見つかった血液異常のBasic
    1-2　健康診断で見つかった血液異常のPractice


    Part D　診断・治療後のアプローチ

    診断・治療後のフォローを依頼されたら
    1 フォローを依頼された場合のBasic & Practice
    1-1　フォローを依頼された場合のBasic
    1-2　フォローを依頼された場合のPractice

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part A 検査所見からのアプローチ

P.2 掲載の参考文献
1) World Health Organization:Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. World Health Organization, 2011(WHO/NMH/NHD/MNM/11.1). http://www.who.int/vmnis/indicators/haemoglobin.pdf(2022年2月閲覧)
 
2) 白倉卓夫, 他:老年者末梢血像と赤血球産生能の変化. 日老医誌 1978;15:151-157.
 
3) 樋口敬和:血算(全血球計算)の読み方. In:矢崎義雄 監修, 徳田安春, 他 編:新臨床内科学, 第10版. 医学書院, 2020:968-973.
 
4) Means RT, et al.:Anemia:general considerations. In:Greer JP, et al., eds, Wintrobe's Clinical Hematology, 14th ed. Wolters Kluwer, 2019;588-614.
 
5) 樋口敬和:貧血の鑑別のアプローチは? In:神田善伸 編:むかしの頭で診ていませんか? 血液診療をスッキリまとめました. 南江堂, 2017:1-7.
 
6) Nardone DA, et al.:Usefulness of physical examination in detecting the presence or absence of anemia. Arch Intern Med 1990;150:201-204.
PubMed
7) Kalantri A, et al.:Accuracy and reliability of pallor for detecting anaemia:A hospital-based diagnostic accuracy study. PLoS One 2010;5:e8545.
PubMed
8) Strobach RS, et al.:The value of the physical examination in the diagnosis of anemia. correlation of the physical findings and the hemoglobin concentration. Arch Intern Med 1988;148:831-832.
PubMed
9) Sheth TN, et al.:The relation of conjunctival pallor to the presence of anemia. J Gen Intern Med 1997;12:102-106.
 
10) Nardone DA, et al.:Usefulness of physical examination in detecting the presence or absence of anemia. Arch Intern Med 1990;150:201-204.
PubMed
11) McGee S 著, 徳田安春 総監訳, 志水太郎, 他 監訳:マクギーのフィジカル診断学, 原著第4版. 診断と治療社, 2019:65(McGee S:Evidence-Based Physical Diagnosis, 4th ed. Elsevier, 2017).
 
12) World Health Organization:Serum ferritin concentrations for the assessment of iron status in individuals and populations:technical brief. World Health Organization, 2020. https://apps.who.int/iris/handle/10665/337666(2022年2月閲覧)
 
13) Camaschella C:Iron-deficiency anemia. N Engl J Med 2015;372:1832-1843.
PubMed
14) Lopez A, et al.:Iron deficiency anaemia. Lancet 2016;387:907-916.
PubMed
15) Pasricha S, et al.:Iron deficiency. Lancet 2021;397:233-248.
PubMed
16) Krayenbuehl P, et al.:Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011;118:3222-3227.
PubMed
17) Houston BL, et al.:Efficacy of iron supplementation on fatigue and physical capacity in non-anaemic iron-deficient adults:A systematic review of randomised controlled trials. BMJ Open 2018;8:e019240.
PubMed
18) Munoz M, et al.:Current misconceptions in diagnosis and management of iron deficiency. Blood Transfus 2017;15:422-437.
PubMed
19) Elstrott B, et al.:The role of iron repletion in adult iron deficiency anemia and other diseases. Eur J Haematol 2020;104:153-161.
PubMed
20) Girelli D, et al.:Modern iron replacement therapy:Clinical and pathophysiological insights. Int J Hematol 2018;107:16-30.
PubMed
21) 山城安啓:サラセミアの基礎知識と臨床検査. Med Technol 2015;43:1110-1117.
Medical*Online
22) Taher AT, et al.:Thalassaemia. Lancet 2018;391:155-167.
PubMed
23) Ganz T:Anemia of inflammation. N Engl J Med 2019;381:1148-1157.
 
24) Fraenkel PG:Anemia of inflammation:A review. Med Clin North Am 2017;101:285-296.
 
25) Poggiali E, et al.:Anemia of chronic disease:A unique defect of iron recycling for many different chronic diseases. Eur J Intern Med 2014;25:12-17.
PubMed
26) Gangat N, et al.:Anemia of chronic disease. Semin Hematol 2013;50:232-238.
PubMed
27) 赤芽球癆診療の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ:赤芽球癆診療の参照ガイド令和1年改訂版(第6版). 厚生労働科学研究費補助金 難治性疾患等政策研究事業 特発性造血障害に関する調査研究班(研究代表者 三谷絹子), 2020. http://zoketsushogaihan.umin.jp/file/2020/03.pdf(2022年2月閲覧)
 
28) 廣川誠:赤芽球癆診療の進歩と今後の展望. 臨血 2016;57:110-116.
 
29) Means RT:Pure red cell aplasia. Blood 2016;128:2504-2509.
PubMed
30) Hirokawa M, et al.:Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia:A nationwide cohort study in japan by the PRCA collaborative study group. Haematologica 2008;93:27-33.
 
31) 発作性夜間ヘモグロビン尿症(PNH)の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ:発作性夜間ヘモグロビン尿症診療の参照ガイド令和1年改訂版. 厚生労働科学研究費補助金 難治性疾患等政策研究事業 特発性造血障害に関する調査研究班(研究代表者 三谷絹子), 2020. http://zoketsushogaihan.umin.jp/file/2020/06v2.pdf(2022年2月閲覧)
 
32) 後藤明彦:発作性夜間ヘモグロビン尿症診療の参照ガイド-最近のアップデートと診療のポイント. 臨血 2020;61:1080-1088.
 
33) Brodsky RA:Paroxysmal nocturnal hemoglobinuria. Blood 2014;124:2804-2811.
PubMed
34) Devalet B, et al.:Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria:A review. Eur J Haematol 2015;95:190-198.
PubMed
35) Capecchi M, et al.:Thrombotic complications in patients with immune-mediated hemolysis. J Clin Med 2021;10:1764.
PubMed
36) Hillmen P, et al.:Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013;162:62-73.
PubMed
37) Lee JW, et al.:Ravulizumab(ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors:The 301 study. Blood 2019;133:530-539.
PubMed
38) Kulasekararaj AG, et al.:Ravulizumab(ALXN1210) vs eculizumab in C5-inhibitorexperienced adult patients with PNH:The 302 study. Blood 2019;133:540-549.
 
39) Takahashi N, et al.:Causes of macrocytic anemia among 628 patients:mean corpuscular volumes of 114 and 130 fL as critical markers for categorization. Int J Hematol 2016;104:344-357.
PubMed
40) Wickramasinghe SN:Diagnosis of megaloblastic anaemias. Blood Rev 2006;20:299-318.
PubMed
41) Snow CF:Laboratory diagnosis of vitamin B12 and folate deficiency:A guide for the primary care physician. Arch Intern Med 1999;159:1289-1298.
PubMed
42) Stabler SP:Clinical practice. vitamin B12 deficiency. N Engl J Med 2013;368:149-160.
PubMed
43) 樋口敬和:鉄剤・葉酸・ビタミンB12. In:中尾眞二, 他 編:血液疾患最新の治療2020-2022. 南江堂, 2019:61-64.
 
44) Carmel R:How I treat cobalamin(vitamin B12) deficiency. Blood 2008;112:2214-2221.
 
45) Shipton MJ, et al.:Vitamin B12 deficiency-A 21st century perspective. Clin Med (Lond) 2015;15:145-150.
PubMed
46) Andres E, et al.:Oral cobalamin(vitamin B(12)) treatment. an update. Int J Lab Hematol 2009;31:1-8.
PubMed
47) Mahmoud MY, et al.:Unexplained macrocytosis in elderly patients. Age Ageing 1996;25:310-312.
PubMed
48) 自己免疫性溶血性貧血の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ:自己免疫性溶血性貧血診療の参照ガイド 令和1年改訂版. 厚生労働科学研究費補助金 難治性疾患等政策研究事業 特発性造血障害に関する調査研究班(研究代表者 三谷絹子), 2020. http://zoketsushogaihan.umin.jp/file/2020/09.pdf(2022年2月閲覧)
 
49) Jager U, et al.:Diagnosis and treatment of autoimmune hemolytic anemia in adults:Recommendations from the first international consensus meeting. Blood Rev 2020;41:100648.
PubMed
50) Hill QA, et al.:The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol 2017;176:395-411.
PubMed
51) Brodsky RA:Warm autoimmune hemolytic anemia. N Engl J Med 2019;381:647-654.
PubMed
52) Berentsen S, et al.:Autoimmune hemolytic anemias. N Engl J Med 2021;385:1407-1419.
PubMed
53) Spivak JL:Masked megaloblastic anemia. Arch Intern Med 1982;142:2111-2114.
PubMed
54) Hash RB, et al.:Anemia secondary to combined deficiencies od iron and cobalamin. Arch Fam Med 1996;5:585-588.
 
P.36 掲載の参考文献
1) [環自総発第1407012号]環境省自然環境局長:「温泉法第18条第1項の規定に基づく禁忌症及び入浴又は飲用上の注意の掲示等の基準」及び「鉱泉分析法指針(平成26年改訂)」について. 2014. https://www.env.go.jp/nature/onsen/docs/kyokucho.pdf(2022年2月閲覧)
 
2) Le Conseil National des Etablissements Thermaux(CNETh):La medecine thermal. http://www.medecinethermale.fr(2022年2月閲覧)
 
P.38 掲載の参考文献
1) McMullin MF:The classification and diagnosis of erythrocytosis. Int J Lab Hematol 2008;30:447-459.
PubMed
2) Patnaik MM, et al.:The complete evaluation of erythrocytosis:Congenital and acquired. Leukemia 2009;23:834-844.
PubMed
3) Lee G, et al.:The clinical and laboratory evaluation of the patient with erythrocytosis. Eur J Intern Med 2015;26:297-302.
PubMed
4) Parnes A, et al.:Polycythemia and thrombocytosis. Prim Care 2016;43:589-605.
PubMed
5) Remacha AF, et al.:Serum erythropoietin in the diagnosis of polycythemia vera. A follow-up study. Haematologica 1997;82:406-410.
PubMed
6) Mossuz P, et al.:Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004;89:1194-1198.
PubMed
7) Nordenberg D, et al.:The effect of cigarette smoking on hemoglobin levels and anemia screening. JAMA 1990;264:1556-1559.
PubMed
8) Krishnamoorthy P, et al.:Gaisbock syndrome(polycythemia and hypertension) revisited:Results from the national inpatient sample database. J Hypertens 2018;36:2420-2424.
PubMed
9) Moore-Gillon JC, et al.:Intermittent hypoxia in patients with unexplained polycythaemia. Br Med J 1986;293:588-590.
 
10) Solmaz S, et al.:Is obstructive sleep apnoea syndrome really one of the causes of secondary polycythaemia? Hematology 2015;20:108-111.
PubMed
11) Nguyen CD, et al.:Does untreated obstructive sleep apnea cause secondary erythrocytosis? Respir Med 2017;130:27-34.
PubMed
12) Thiele J, et al.:Polycythaemia vera. In:Swerdlow SH, et al., eds.:WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th ed. IARC, 2017:39-43.
 
13) Spivak JL:Myeloproliferative neoplasms. N Engl J Med 2017;376:2168-2181.
PubMed
14) McMullin MF, et al.:A guideline for the diagnosis and management of polycythaemia vera. A British society for Haematology guideline. Br J Haematol 2019;184:176-191.
PubMed
15) Tefferi A, et al.:Polycythemia vera and essential thrombocythemia:2021 update on diagnosis, risk-stratification and management. Am J Hematol 2020;95:1599-1613.
PubMed
16) Marchioli R, et al.:Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368:22-33.
PubMed
17) Vannucchi AM, et al.:Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015;372:426-435.
PubMed
18) Passamonti F, et al.:Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly(RESPONSE-2):A randomised, openlabel, phase 3 b study. Lancet Oncol 2017;18:88-99.
 
19) Wajcman H, et al.:Hemoglobins with high oxygen affinity leading to erythrocytosis. new variants and new concepts. Hemoglobin 2005;29:91-106.
PubMed
20) Wannamethee G, et al.:Ischaemic heart disease:Association with haematocrit in the British regional heart study. J Epidemiol Community Health 1994;48:112-118.
PubMed
21) Danesh J, et al.:Haematocrit, viscosity, erythrocyte sedimentation rate:Metaanalyses of prospective studies of coronary heart disease. Eur Heart J 2000;21:515-520.
PubMed
P.54 掲載の参考文献
1) Bessmann JD, et al.:Improved classification of anemias by MCV and RDW. Am J Clin Pathol 1983;80:322-326.
 
2) Zhou A, et al.:Hematologic disorders and transfusion therapy. In:Crees Z, et al., eds.:Washington Manual of Medical Therapeutics, 36th ed., Wolters Kluwer, 2019:706-740.
 
P.56 掲載の参考文献
1) Andersen CL, et al.:Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts:A longitudinal study. J Intern Med 2016;279:566-575.
PubMed
2) Newburger PE, et al.:Evaluation and management of patients with isolated neutropenia. Semin Hematol 2013;50:198-206.
PubMed
3) Castelino DJ, et al.:Lymphocytopenia in a hospital population--what does it signify? Aust N Z J Med 1997;27:170-174.
 
4) Palmblad J, et al.:Ethnic benign neutropenia:A phenomenon finds an explanation. Pediatr Blood Cancer 2018;65:e27361.
PubMed
5) Gibson C, et al.:How we evaluate and treat neutropenia in adults. Blood 2014;124:1251-1258;quiz 1378.
 
6) Dale DC:How I diagnose and treat neutropenia. Curr Opin Hematol 2016;23:1-4.
 
7) Palmblad J, et al.:How we diagnose and treat neutropenia in adults. Expert Rev Hematol 2016;9:479-487.
PubMed
8) Newburger PE:Autoimmune and other acquired neutropenias. Hematology Am Soc Hematol Educ Program 2016;2016:38-42.
PubMed
9) Temple RW, et al.:Thrombocytopenia and neutropenia:A structured approach to evaluation. J Fam Pract 2018;67:E1-E8.
PubMed
10) 日本臨床腫瘍学会:発熱性好中球減少症(FN)診療ガイドライン, 改訂第2版. 南江堂, 2017.
 
11) Freifeld AG, et al.:Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer:2010 update by the infectious diseases society of america. Clin Infect Dis 2011;52:e56-e93.
 
12) Smith TJ, et al.:Recommendations for the use of WBC growth factors:American society of clinical oncology clinical practice guideline update. J Clin Oncol 2015;33:3199-3212.
 
13) Taplitz RA, et al.:Outpatient management of fever and neutropenia in adults treated for malignancy:American society of clinical oncology and infectious diseases society of america clinical practice guideline update. J Clin Oncol 2018;36:1443-1453.
 
14) Vicente N, et al.:Antithyroid drug-induced agranulocytosis:State of the art on diagnosis and management. Drugs R D 2017;17:91-96.
PubMed
15) Wang Y, et al.:Granulocyte-colony-stimulating factor effectively shortens recovery duration in anti-thyroid-drug-induced agranulocytosis:A systematic review and meta-analysis. Front Endocrinol(Lausanne) 2019;10:789.
PubMed
16) Andersohn F, et al.:Systematic review:Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2007;146:657-665.
PubMed
17) Curtis BR:Non-chemotherapy drug-induced neutropenia:Key points to manage the challenges. Hematology Am Soc Hematol Educ Program 2017;2017:187-193.
PubMed
18) Valent P, et al.:Idiopathic cytopenia of undetermined significance(ICUS) and idiopathic dysplasia of uncertain significance(IDUS), and their distinction from low risk MDS. Leuk Res 2012;36:1-5.
PubMed
19) Malcovati L, et al.:The shadowlands of MDS:Idiopathic cytopenias of undetermined significance(ICUS) and clonal hematopoiesis of indeterminate potential(CHIP). Hematology Am Soc Hematol Educ Program 2015;2015:299-307.
PubMed
20) 横山泰久, 他:成人慢性好中球減少症診療の参照ガイド. 臨血 2018;59:845-857.
 
21) Dale DC, et al.:An update on the diagnosis and treatment of chronic idiopathic neutropenia. Curr Opin Hematol 2017;24:46-53.
PubMed
22) Fattizzo B, et al.:Is chronic neutropenia always a benign disease? evidences from a 5-year prospective study. Eur J Intern Med 2015;26:611-615.
PubMed
23) Castelino DJ, et al.:Lymphocytopenia in a hospital population-what does it signify? Aust NZ J Med 1997;27:170-174.
 
24) Brass D, et al.:Investigating an incidental finding of lymphopenia. BMJ 2014;348:g1721.
PubMed
25) Vila LM, et al.:Systemic lupus erythematosus in a multiethnic US cohort, XXXVII:Association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. Arthritis Rheum 2006;55:799-806.
 
26) Aringer M, et al.:2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019;78:1151-1159.
PubMed
P.75 掲載の参考文献
1) Riley LK, et al.:Evaluation of patients with leukocytosis. Am Fam Physician 2015;92:1004-1011.
PubMed
2) Abramson N, et al.:Leukocytosis:Basics of clinical assessment. Am Fam Physician 2000;62:2053-2060.
PubMed
3) Chabot-Richards DS, et al.:Leukocytosis. Int J Lab Hematol 2014;36:279-288.
PubMed
4) George TI:Malignant or benign leukocytosis. Hematology Am Soc Hematol Educ Program 2012;2012:475-484.
 
5) Frohlich M, et al.:Independent association of various smoking characteristics with markers of systemic inflammation in men. results from a representative sample of the general population(MONICA Augsburg survey 1994/95). Eur Heart J 2003;24:1365-1372.
PubMed
6) Smith MR, et al.:Smoking status and differential white cell count in men and women in the EPIC-Norfolk population. Atherosclerosis 2003;169:331-337.
PubMed
7) Higuchi T, et al.:Current cigarette smoking is a reversible cause of elevated white blood cell count:Cross-sectional and longitudinal studies. Prev Med Rep 2016;4:417-422.
PubMed
8) Smith CJ, et al.:Leukocytosis and tobacco use:An observational study of asymptomatic leukocytosis. Am J Med 2021;134:e31-e35.
PubMed
9) 樋口敬和:白血球分画異常-異型リンパ球, 好酸球増加, 白赤芽球症. medicina 2014;51:435-439.
 
10) Papac RJ:Bone marrow metastases. A review. Cancer 1994;74:2403-2413.
PubMed
11) Arber DA, et al.:Acute myeloid leukemia and related precursor neoplasms. In:Swerdlow SH, et al., eds.:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed. IARC, 2017:129-171.
 
12) Dohner H, et al.:Diagnosis and management of AML in adults:2017 ELN recommendations from an international expert panel. Blood 2017;129:424-447.
 
13) Malard F, et al.:Acute lymphoblastic leukaemia. Lancet 2020;395:1146-1162.
PubMed
14) 急性骨髄性白血病. In:日本血液学会 編:造血器腫瘍診療ガイドライン2018年版補訂版. 金原出版, 2020:8-37.
 
15) Short NJ, et al.:Acute myeloid leukaemia. Lancet 2018;392:593-606.
PubMed
16) 急性リンパ芽球性白血病/リンパ芽球性リンパ腫. In:日本血液学会 編:造血器腫瘍診療ガイドライン2018年版補訂版. 金原出版, 2020:59-88.
 
17) Muffly L, et al.:Philadelphia chromosome positive acute lymphoblastic leukemia in adults:Therapeutic options and dilemmas in 2020. Semin Hematol 2020;57:137-141.
PubMed
18) Jabbour E, et al.:Chronic myeloid leukemia:2020 update on diagnosis, therapy and monitoring. Am J Hematol 2020;95:691-709.
PubMed
19) Hochhaus A, et al.:European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34:966-984.
PubMed
20) Hochhaus A, et al.:Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017;376:917-927.
PubMed
21) Saglio G, et al.:Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259.
PubMed
22) Kantarjian HM, et al.:Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase:ENESTnd 10-year analysis. Leukemia 2021;35:440-453.
PubMed
23) Kantarjian H, et al.:Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-2270.
PubMed
24) Cortes JE, et al.:Final 5-year study results of DASISION:The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol 2016;34:2333-2340.
 
25) Cortes J, et al.:Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol 2019;94:346-357.
PubMed
26) Etienne G, et al.:Long-term follow-up of the French Stop Imatinib(STIM1) Study in patients with chronic myeloid leukemia. J Clin Oncol 2017;35:298-305.
PubMed
27) Imagawa J, et al.:Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial):A multicentre phase 2 trial. Lancet Haematol 2015;2:e528-e535.
 
28) Marti GE, et al.:Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 2005;130:325-332.
PubMed
29) 日本臨床衛生技師会血液形態検査標準化ワーキンググループ:血液形態検査に関する勧告法. 医学検査 1996;45:1659-1671.
 
30) Porwit A:Clinical flow cytometry. In:Greer JP, et al., eds.:Wintrobe's Clinical Hematology, 14th ed. Wolters Kluwer, 2019:17-46.
 
31) 米山彰子:表面形質検査. In:日本血液学会 編:血液専門医テキスト, 改訂第3版. 南江堂, 2019:61-66.
 
32) 増田亜希子:細胞表面マーカー解析. 内科 2019;124:2063-2068.
 
33) Hallek M, et al.:Chronic lymphocytic leukaemia. Lancet 2018;391:1524-1537.
PubMed
34) Strati P, et al.:Chronic lymphocytic leukemia:Diagnosis and treatment. Mayo Clin Proc 2018;93:651-664.
PubMed
35) Hallek M, et al.:iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018;131:2745-2760.
PubMed
36) 慢性リンパ性白血病/小リンパ球性リンパ腫. In:日本血液学会 編:造血器腫瘍診療ガイドライン2018年版補訂版. 金原出版, 2020:121-188.
 
37) Woyach JA, et al.:Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018;379:2517-2528.
PubMed
38) Byrd JC, et al.:Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia:Final analysis of the pivotal phase Ib/II PCYC-1102 study. Clin Cancer Res 2020;26:3918-3927.
PubMed
39) Valent P, et al.:Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012;130:607-612. e9.
 
40) Butt NM, et al.:Guideline for the investigation and management of eosinophilia. Br J Haematol 2017;176:553-572.
PubMed
41) Shomali W, et al.:World Health Organization-defined eosinophilic disorders:2019 update on diagnosis, risk stratification, and management. Am J Hematol 2019;94:1149-1167.
PubMed
42) Larsen RL, et al.:How I investigate eosinophilia. Int J Lab Hematol 2019;41:153-161.
 
43) 樋口敬和:好酸球増多の鑑別診断. 内科 2020;126:723-727.
 
44) 定明子, 他:本邦における慢性好酸球性白血病/特発性好酸球増多症候群の臨床像と治療. 臨血 2010;51:515-525.
 
45) Reiter A, et al.:Myeloid neoplasms with eosinophilia. Blood 2017;129:704-714.
PubMed
46) Helbig G, et al.:T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. Haematologica 2009;94:1236-1241.
PubMed
47) Lefevre G, et al.:The lymphoid variant of hypereosinophilic syndrome:Study of 21 patients with CD3-CD4+ aberrant T-cell phenotype. Medicine(Baltimore) 2014;93:255-266.
PubMed
48) Lynch DT, et al.:How I investigate monocytosis. Int J Lab Hematol 2018;40:107-114.
 
49) Valent P, et al.:Proposed diagnostic criteria and classification of basophilic leukemias and related disorders. Leukemia 2017;31:788-797.
PubMed
50) Feriel J, et al.:How I investigate basophilia in daily practice. Int J Lab Hematol 2020;42:237-245.
 
P.114 掲載の参考文献
1) Simon MW:The atypical lymphocyte. Int Pediatr 2003;18:20-22.
 
2) van der Meer W, et al.:The divergent morphological classification of variant lymphocytes in blood smears. J Clin Pathol 2007;60:838-839.
PubMed
3) 阿南建一:リンパ球系細胞の見方-異型リンパ球と異常リンパ球の違い. 検と技 2016;44:1150-1156.
 
4) 日本臨床衛生検査技師会血液形態検査標準化ワーキンググループ:血液形態検査に関する勧告法. 医学検査 1996;45:1659-1671.
 
5) Hurt C, et al.:Diagnostic evaluation of mononucleosis-like illnesses. Am J Med 2007;120:911. e1-911. e8.
 
6) Ebell MH:Epstein-Barr virus infectious mononucleosis. Am Fam Physician 2004;70:1279-1287.
PubMed
7) Lennon P, et al.:Infectious mononucleosis. BMJ 2015;350:h1825.
PubMed
P.120 掲載の参考文献
1) Huang ME, et al.:Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-572.
PubMed
2) Shen ZX, et al.:Use of arsenic trioxide(As2O3)in the treatment of acute promyelocytic leukemia(APL):II. clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-3360.
PubMed
P.122 掲載の参考文献
1) Wong EY, et al.:Why does my patient have thrombocytopenia? Hematol Oncol Clin North Am 2012;26:231-252.
PubMed
2) Sekhon SS, et al.:Thrombocytopenia in adults:A practical approach to evaluation and management. South Med J 2006;99:491-500, 533.
PubMed
3) Stasi R:How to approach thrombocytopenia. Hematology Am Soc Hematol Educ Program 2012;2012:191-197.
PubMed
4) Bizzaro N:EDTA-dependent pseudothrombocytopenia:A clinical and epidemiological study of 112 cases, with 10-year follow-up. Am J Hematol 1995;50:103-109.
PubMed
5) 西郷勝康, 他:EDTA 依存性偽性血小板減少症の臨床と検査. 臨病理 2005;53:646-653.
Medical*Online
6) Rodeghiero F, et al.:Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children:Report from an international working group. Blood 2009;113:2386-2393.
 
7) Lambert MP, et al.:Clinical updates in adult immune thrombocytopenia. Blood 2017;129:2829-2835.
PubMed
8) Cooper N, et al.:Immune thrombocytopenia. N Engl J Med 2019;381:945-955.
PubMed
9) Westerman DA, et al.:The diagnosis of idiopathic thrombocytopenic purpura in adults:Does bone marrow biopsy have a place? Med J Aust 1999;170:216-217.
PubMed
10) 柏木浩和, 他:成人特発性血小板減少性紫斑病治療の参照ガイド2019改訂版. 臨血 2019;60:877-896.
 
11) Provan D, et al.:International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-186.
PubMed
12) Neunert C, et al.:American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019;3:3829-3866.
PubMed
13) Stasi R, et al.:Effects of eradication of helicobacter pylori infection in patients with immune thrombocytopenic purpura:A systematic review. Blood 2009;113:1231-1240.
PubMed
14) Ghanima W, et al.:How I treat immune thrombocytopenia:The choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012;120:960-969.
PubMed
15) Bussel JB, et al.:Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura:A randomised, doubleblind, placebo-controlled trial. Lancet 2009;373:641-648.
PubMed
16) Cheng G, et al.:Eltrombopag for management of chronic immune thrombocytopenia(RAISE):A 6-month, randomised, phase 3 study. Lancet 2011;377:393-402.
 
17) Saleh MN, et al.:Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia:Results of the long-term, open-label EXTEND study. Blood 2013;121:537-545.
 
18) Kuter DJ, et al.:Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010;363:1889-1899.
 
19) Zaja F, et al.:Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010;115:2755-2762.
PubMed
20) Arnold DM, et al.:A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood 2012;119:1356-1362.
PubMed
21) Gangireddy VGR, et al.:Management of thrombocytopenia in advanced liver disease. Can J Gastroenterol Hepatol 2014;28:558-564.
PubMed
P.133 掲載の参考文献
1) Vinholt PJ, et al.:An overview of platelet indices and methods for evaluating platelet function in thrombocytopenic patients. Eur J Haematol 2014;92:367-376.
PubMed
2) Leader A, et al.:Are platelet volume indices of clinical use? A multidisciplinary review. Ann Med 2012;44:805-816.
PubMed
3) Benlachgar N, et al.:Immature platelets:A review of the available evidence. Thromb Res 2020;195:43-50.
PubMed
4) Buttarello M, et al.:Reticulated platelets and immature platelet fraction:Clinical applications and method limitations. Int J Lab Hematol 2020;42:363-370.
PubMed
5) Briggs C, et al.:Assessment of an immature platelet fraction(IPF) in peripheral thrombocytopenia. Br J Haematol 2004;126:93-99.
PubMed
6) Sakuragi M, et al.:Clinical significance of IPF% or RP% measurement in distinguishing primary immune thrombocytopenia from aplastic thrombocytopenic disorders. Int J Hematol 2015;101:369-375.
PubMed
P.135 掲載の参考文献
1) Schafer AI:Thrombocytosis. N Engl J Med 2004;350:1211-1219.
PubMed
2) Harrison CN, et al.:Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010;149:352-375.
PubMed
3) Griesshammer M, et al.:Aetiology and clinical significance of thrombocytosis:Analysis of 732 patients with an elevated platelet count. J Intern Med 1999;245:295-300.
PubMed
4) Holbro A, et al.:Iron deficiency and thrombocytosis. Vox Sang 2017;112:87-92.
PubMed
5) Akan H, et al.:Thrombopoietic cytokines in patients with iron deficiency anemia with or without thrombocytosis. Acta Haematol 2000;103:152-156.
PubMed
6) Bailey SE, et al.:Clinical relevance of thrombocytosis in primary care:A prospective cohort study of cancer incidence using English electronic medical records and cancer registry data. Br J Gen Pract 2017;67:e405-e413.
 
7) Bailey SER, et al.:How useful is thrombocytosis in predicting an underlying cancer in primary care? a systematic review. Fam Pract 2017;34:4-10.
PubMed
8) Lin RJ, et al.:Paraneoplastic thrombocytosis:The secrets of tumor self-promotion. Blood 2014;124:184-187.
PubMed
9) Tefferi A, et al.:Essential thrombocythemia. N Engl J Med 2019;381:2135-2144.
PubMed
10) Thiele J, et al.:Essential thrombocythaemia. In:Swerdlow SH, et al., eds.:WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th ed. IARC, 2017:50-56.
 
11) 慢性骨髄性白血病/骨髄増殖性腫瘍. In:日本血液学会 編:造血器腫瘍診療ガイドライン2018年版補訂版. 金原出版, 2020:89-120.
 
12) Tefferi A, et al.:Polycythemia vera and essential thrombocythemia:2021 update on diagnosis, risk-stratification and management. Am J Hematol 2020;95:1599-1613.
PubMed
13) Barbui T, et al.:Development and validation of an International Prognostic Score of Thrombosis in World Health Organization-Essential Thrombocythemia(IPSETthrombosis). Blood 2012;120:5128-5133:quiz 5252.
 
14) Barbui T, et al.:Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J 2015;5:e369.
PubMed
15) Falchi L, et al.:Approach to patients with essential thrombocythaemia and very high platelet counts:What is the evidence for treatment? Br J Haematol 2017;176:352-364.
PubMed
16) Birgegard G:The use of anagrelide in myeloproliferative neoplasms, with focus on essential thrombocythemia. Curr Hematol Malig Rep 2016;11:348-355.
PubMed
17) Awada H, et al.:Essential thrombocythemia and acquired von Willebrand syndrome:The shadowlands between thrombosis and bleeding. Cancers(Basel) 2020;12:1746.
 
18) Robinson SE, et al.:How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy. Br J Haematol 2020;189:625-634.
PubMed
19) Edahiro Y, et al.:Interferon therapy for pregnant patients with essential thrombocythemia in Japan. Int J Hematol 2021;113:106-111.
PubMed
P.148 掲載の参考文献
1) Gnanaraj J, et al.:Approach to pancytopenia:Diagnostic algorithm for clinical hematologists. Blood Rev 2018;32:361-367.
PubMed
2) Imbert M, et al.:Adult patients presenting with pancytopenia:A reappraisal of underlying pathology and diagnostic procedures in 213 cases. Hematol Pathol 1989;3:159-167.
PubMed
3) Devitt KA, et al.:New onset pancytopenia in adults:A review of underlying pathologies and their associated clinical and laboratory findings. Leuk Lymphoma 2014;55:1099-1105.
PubMed
4) Weinzierl EP, et al.:Bone marrow evaluation in new-onset pancytopenia. Hum Pathol 2013;44:1154-1164.
PubMed
5) Marks PW:Hematologic manifestations of liver disease. Semin Hematol 2013;50:216-221.
PubMed
6) Kusumoto S, et al.:Bone marrow patterns in patients with aplastic anaemia and myelodysplastic syndrome:Observations with magnetic resonance imaging. Eur J Haematol 1997;59:155-161.
PubMed
7) 再生不良性貧血の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ:再生不良性貧血診療の参照ガイド 令和1年改訂版. 厚生労働科学研究費補助金 難治性疾患等政策研究事業 特発性造血障害に関する調査研究班(研究代表者 三谷絹子), 2020. http://zoketsushogaihan.umin.jp/file/2020/02.pdf(2022年2月閲覧)
 
8) Young NS:Aplastic anemia. N Engl J Med 2018;379:1643-1656.
PubMed
9) Olnes MJ, et al.:Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012;367:11-19.
PubMed
10) Townsley DM, et al.:Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med 2017;376:1540-1550.
PubMed
11) Arber DA, et al.:Acute myeloid leukaemia with recurrent genetic changes. In:Swerdlow SH, et al., eds.:WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th ed. IARC, 2017:130-149.
 
12) Sanz MA, et al.:Management of acute promyelocytic leukemia:Updated recommendations from an expert panel of the European LeukemiaNet. Blood 2019;133:1630-1643.
 
13) 急性前骨髄球性白血病.In:日本血液学会 編:造血器腫瘍診療ガイドライン2018年版補訂版. 金原出版, 2020:38-58.
 
14) Burnett AK, et al.:Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups(AML17):Results of a randomised, controlled, phase 3 trial. Lancet Oncol 2015;16:1295-1305.
PubMed
15) Platzbecker U, et al.:Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia:Final results of the randomized Italian-German APL0406 trial. J Clin Oncol 2017;35:605-612.
 
16) Shinagawa K, et al.:Tamibarotene as maintenance therapy for acute promyelocytic leukemia:Results from a randomized controlled trial. J Clin Oncol 2014;32:3729-3735.
PubMed
17) Mantha S, et al.:Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood 2017;129:1763-1767.
PubMed
18) Stahl M, et al.:Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol 2019;187:157-162.
PubMed
19) Brunning RD, et al.:Myelodusplastic syndromes. In:Swerdlow SH, et al., eds.:WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th ed. IARC, 2017:106-149120.
 
20) Cazzola M:Myelodysplastic syndromes. N Engl J Med 2020;383:1358-1374.
PubMed
21) Greenberg PL, et al.:Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood 2012;120:2454-2465.
PubMed
22) 骨髄異形成症候群の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ:骨髄異形成症候群診療の参照ガイド 令和1年改訂版. 厚生労働科学研究費補助金 難治性疾患等政策研究事業 特発性造血障害に関する調査研究班(研究代表者 三谷絹子), 2020. http://zoketsushogaihan.umin.jp/file/2020/04v2.pdf(2022年2月閲覧)
 
23) Fenaux P, et al.:Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes:A randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232.
PubMed
24) 血液製剤の使用にあたって, 第5版. じほう, 2017.
 
25) 米村雄士, 他:科学的根拠に基づいた赤血球製剤の使用ガイドライン. 日輸血細胞治療会誌 2016;62:641-650.
Medical*Online
26) 樋口敬和:輸血すべき貧血と輸血を避けるべき貧血. 診断と治療 2019;107:591-594.
Medical*Online
27) 輸血後鉄過剰症の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ:輸血後鉄過剰症診療の参照ガイド 令和1年改訂版. 厚生労働科学研究費補助金 難治性疾患等政策研究事業 特発性造血障害に関する調査研究班(研究代表者 三谷絹子), 2020. http://zoketsushogaihan.umin.jp/file/2020/05.pdf(2022年2月閲覧)
 
28) Brittenham GM:Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011;364:146-156.
PubMed
29) 高見昭良, 他:科学的根拠に基づいた血小板製剤の使用ガイドライン-2019年改訂版. 日輸血細胞治療会誌 2019;65:544-561.
Medical*Online
P.167 掲載の参考文献
1) 山田俊幸:血清タンパク. 日本医師会雑誌 2021;150 特別1:S95-S101.
 
2) O'Connell TX, et al.:Understanding and interpreting serum protein electrophoresis. Am Fam Physician 2005;71:105-112.
PubMed
3) Glavey SV, et al.:Monoclonal gammopathy:The good, the bad and the ugly. Blood Rev 2016;30:223-231.
PubMed
4) Eby C:Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol 2009;145:151-163.
PubMed
5) 日本骨髄腫学会 編:多発性骨髄腫の診療指針, 第5版. 文光堂, 2020.
 
6) Rajkumar SV, Dimopoulos MA, Palumbo A, et al.:International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:538, 2014
 
7) 西村倫子:血清フリーライトチェーン. 最新医67:1396-1402, 2012
 
8) Dispenzieri A, et al.:International Myeloma Working Group guidelines for serumfree light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-224.
 
9) Greipp PR, et al.:International Staging System for multiple myeloma. J Clin Oncol 2005;23:3412-3420.
PubMed
10) Palumbo A, et al.:Revised International Staging System for multiple myeloma:A report from International Myeloma Working Group. J Clin Oncol 2015;33:2863-2869.
 
11) 多発性骨髄腫. In:日本血液学会 編:造血器腫瘍診療ガイドライン2018年版補訂版. 金原出版, 2020:320-367.
 
12) Mateos M, et al.:Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 2018;378:518-528.
PubMed
13) Facon T, et al.:Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019;380:2104-2115.
PubMed
14) Iwanaga M, et al.:Prevalence of monoclonal gammopathy of undetermined significance:Study of 52,802 persons in Nagasaki City, Japan. Mayo Clin Proc 2007;82:1474-1479.
PubMed
15) van de Donk NW, et al.:Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Int J Lab Hematol 2016;38 Suppl 1:110-122.
 
16) van de Donk, NW, et al.:The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders:Recommendations from the European Myeloma Network. Haematologica 2014;99:984-996.
PubMed
17) Owen RG, et al.:Guidelines on the diagnosis and management of Waldenstrom macroglobulinaemia. Br J Haematol 2014;165:316-333.
 
18) D'Souza A, et al.:Waldenstrom macroglobulinaemia:The key questions. Br J Haematol 2013;162:295-303.
 
19) リンパ形質細胞性リンパ腫/ワルデンシュトレームマクログロブリン血症. In:日本血液学会 編:造血器腫瘍診療ガイドライン2018年版補訂版. 金原出版, 2020:208-214.
 
20) Owen RG, et al.:Guidelines on the diagnosis and management of Waldenstrom macroglobulinaemia. Br J Haematol 2014;165:316-333.
 
21) Dimopoulos MA, et al.:Treatment recommendations for patients with Waldenstrom macroglobulinemia(WM) and related disorders:IWWM-7 consensus. Blood 2014;124:1404-1411.
PubMed
22) Leblond V, et al.:Treatment recommendations from the Eighth International Workshop on Waldenstrom's macroglobulinemia. Blood 2016;128:1321-1328.
PubMed

Part B 臨床症状からのアプローチ

P.192 掲載の参考文献
1) Kruse-Jarres R, et al.:Identification and basic management of bleeding disorders in adults. J Am Board Fam Med 2014;27:549-564.
PubMed
2) Paddock M, et al.:Bleeding diatheses:Approach to the patient who bleeds or has abnormal coagulation. Prim Care 2016;43:637-650.
PubMed
3) Boender J, et al.:A diagnostic approach to mild bleeding disorders. J Thromb Haemost 2016;14:1507-1516.
PubMed
4) Rydz N, et al.:Approach to the diagnosis and management of common bleeding disorders. Semin Thromb Hemost 2012;38:711-719.
 
5) 大森司:出血性疾患の診断アプローチ. 臨血 2013;54:1888-1896.
 
6) Massyn MW, et al.:Heyde syndrome:A common diagnosis in older patients with severe aortic stenosis. Age Ageing 2009;38:267-270.
PubMed
7) 一瀬白帝, 他:自己免疫性出血病FXIII/13 診療ガイド. 日血栓止血会誌 2017;28:393-420.
 
8) 日笠聡, 他:von Willebrand 病の診療ガイドライン2021年版. 日血栓止血会誌 2021;32:413-481.
 
9) Leebeek FW, et al.:von Willebrand's disease. N Engl J Med 2016;375:2067-2080.
PubMed
10) Peyvandi F, et al.:The past and future of haemophilia:Diagnosis, treatments, and its complications. Lancet 2016;388:187-197.
PubMed
11) 藤井輝久, 他:日本血栓止血学会 インヒビターのない血友病患者に対する止血治療ガイドライン-2013年改訂版. 日血栓止血会誌 2013;24:619-639.
 
12) 間宮繁夫:単純性紫斑病. In:血液症候群-その他の血液疾患を含めて2, 第2版(別冊日本臨牀 新領域別症候群シリーズ). 日本臨牀社, 2013:488-489.
 
13) 間宮繁夫:老人性紫斑病. In:血液症候群-その他の血液疾患を含めて2, 第2版(別冊日本臨牀 新領域別症候群シリーズ). 日本臨牀社, 2013:490-491.
 
14) 松本雅則, 他:血栓性血小板減少性紫斑病(TTP)診療ガイド2017. 臨血 2017;58:271-281.
 
15) Gunasekaran K, et al.:A review of the incidence diagnosis and treatment of spontaneous hemorrhage in patients treated with direct oral anticoagulants. J Clin Med 2020;9:2984.
PubMed
16) Pollack CV, et al.:Idarucizumab for dabigatran reversal. N Engl J Med 2015;373:511-520.
PubMed
17) Siegal DM, et al.:Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;373:2413-2424.
PubMed
18) 酒井道生, 他:後天性血友病A診療ガイドライン2017年改訂版. 日血栓止血会誌 2017;28:715-747.
 
19) Kruse-Jarres R, et al.:Acquired hemophilia A:Updated review of evidence and treatment guidance. Am J Hematol 2017;92:695-705.
PubMed
20) Audemard-Verger A, et al.:IgA vasculitis(Henoch-Schonlein purpura) in adults:Diagnostic and therapeutic aspects. Autoimmun Rev 2015;14:579-585.
PubMed
21) Reamy BV, et al.:Henoch-Schonlein purpura(IgA vasculitis):Rapid evidence review. Am Fam Physician 2020;102:229-233.
PubMed
P.207 掲載の参考文献
1) 森下英理子:遺伝性血栓性素因の診断と治療. 臨血 2017;58:866-874.
 
2) 山崎雅英:血栓性疾患を診た時の考え方. 日血栓止血会誌 2009;20:481-483.
 
3) Di Nisio M, et al.:Deep vein thrombosis and pulmonary embolism. Lancet 2016;388:3060-3073.
PubMed
4) Johnson ED, et al.:The D-dimer assay. Am J Hematol 2019;94:833-839.
 
5) Delluc A, et al.:Occult cancer screening in patients with venous thromboembolism:Guidance from the SSC of the ISTH. J Thromb Haemost 2017;15:2076-2079.
PubMed
6) Stevens SM, et al.:Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis 2016;41:154-164.
PubMed
7) Connors JM:Thrombophilia testing and venous thrombosis. N Engl J Med 2017;377:1177-1187.
PubMed
8) Colucci G, et al.:Thrombophilia screening revisited:An issue of personalized medicine. J Thromb Thrombolysis 2020;49:618-629.
PubMed
9) Sakata T, et al.:Protein C and antithrombin deficiency are important risk factors for deep vein thrombosis in Japanese. J Thromb Haemost 2004;2:528-530.
PubMed
10) Sakata T, et al.:Prevalence of protein S deficiency in the Japanese general population:The Suita Study. J Thromb Haemost 2004;2:1012-1013.
PubMed
11) Elsebaie MAT, et al.:Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia:A systematic review and meta-analysis. J Thromb Haemost 2019;17:645-656.
PubMed
12) Garcia D, et al.:Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 2018;378:2010-2021.
PubMed
13) Miyakis S, et al.:International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome(APS). J Thromb Haemost 2006;4:295-306.
 
14) Rungjirajittranon T, et al.:A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer 2019;19:184.
 
15) Dan K, et al.:Clinical features of polycythemia vera and essential thrombocythemia in Japan:Retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group. Int J Hematol 2006;83:443-449.
 
16) Kroll MH, et al.:Mechanisms of thrombogenesis in polycythemia vera. Blood Rev 2015;29:215-221.
PubMed
17) Komatsu N, et al.:Real-world, retrospective study evaluating thromboembolic events, associated risk factors, and health-care resource utilization in Japanese patients with polycythemia vera. Int J Hematol 2020;112:176-184.
PubMed
P.217 掲載の参考文献
1) Ferrer R:Lymphadenopathy:Differential diagnosis and evaluation. Am Fam Physician 1998;58:1313-1320.
PubMed
2) Ghirardelli ML, et al.:Diagnostic approach to lymph node enlargement. Haematologica 1999;84:242-247.
PubMed
3) Habermann TM, et al.:Lymphadenopathy. Mayo Clin Proc 2000;75:723-732.
PubMed
4) Bazemore AW, et al.:Lymphadenopathy and malignancy. Am Fam Physician 2002;66:2103-2110.
PubMed
5) Gaddey HL, et al.:Unexplained lymphadenopathy:Evaluation and differential diagnosis. Am Fam Physician 2016;94:896-903.
PubMed
6) Motyckova G, et al.:Why does my patient have lymphadenopathy or splenomegaly? Hematol Oncol Clin North Am 2012;26:395-408, ix.
PubMed
7) Deaver D, et al.:Pathogenesis, diagnosis, and management of Kikuchi-Fujimoto disease. Cancer Control 2014;21:313-321.
PubMed
8) Perry AM, et al.:Kikuchi-Fujimoto disease:A review. Arch Pathol Lab Med 2018;142:1341-1346.
PubMed
9) 花川浩之:組織球性壊死性頸部リンパ節炎. JOHNS 2017;33:1635-1638.
Medical*Online
10) Vassilakopoulos TP, et al.:Application of a prediction rule to select which patients presenting with lymphadenopathy should undergo a lymph node biopsy. Medicine (Baltimore) 2000;79:338-347.
PubMed
11) Tokuda Y, et al.:Assessing the validity of a model to identify patients for lymph node biopsy. Medicine(Baltimore) 2003;82:414-418.
 
12) Steinkamp HJ, et al.:Cervical lymphadenopathy:Ratio of long- to short-axis diameter as a predictor of malignancy. Br J Radiol 1995;68:266-270.
 
13) 山本譲司, 他:可溶性インターロイキン2受容体-sIL-2R. 診断と治療 2009;97:1916-1917.
Medical*Online
14) Rubin LA, et al.:The soluble interleukin-2 receptor:Biology, function, and clinical application. Ann Intern Med 1990;113:619-627.
PubMed
15) Bien E, et al.:Serum soluble interleukin 2 receptor alpha in human cancer of adults and children:A review. Biomarkers 2008;13:1-26.
PubMed
16) Pynnonen MA, et al.:Clinical practice guideline:Evaluation of the neck mass in adults. Otolaryngol Head Neck Surg 2017;157:S1-S30.
PubMed
17) Cheson BD, et al.:Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma:The Lugano classification. J Clin Oncol 2014;32:3059-3068.
PubMed
18) Sehn LH, et al.:Diffuse large B-cell lymphoma. N Engl J Med 2021;384:842-858.
PubMed
19) びまん性大細胞型B細胞リンパ腫. In:日本血液学会 編:造血器腫瘍診療ガイドライン2018年版補訂版. 金原出版, 2020:230-254.
 
20) International Non-Hodgkin's Lymphoma Prognostic Factors Project:A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
 
21) Sehn LH, et al.:The revised International Prognostic Index(R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861.
 
22) Zhou Z, et al.:An enhanced International Prognostic Index(NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123:837-842.
PubMed
23) Garces S, et al.:Clinical, histopathologic, and immunoarchitectural features of dermatopathic lymphadenopathy:An update. Mod Pathol 2020;33:1104-1121.
PubMed
24) Gaulard P, et al.:Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In:Swerdlow SH, et al., eds.:WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition. IARC, 2017:462-464.
 
25) Tokuhira M, et al.:Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma 2012;53:616-623.
PubMed
26) 金子祐子:メソトレキセート関連リンパ増殖疾患. 日臨免疫会誌 2017;40:174-178.
 
27) Salloum E, et al.:Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996;14:1943-1949.
PubMed
28) Inui Y, et al.:Methotrexate-associated lymphoproliferative disorders:Management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. Leuk Lymphoma 2015;56:3045-3051.
PubMed
P.233 掲載の参考文献
1) Horning SJ, et al.:The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984;311:1471-1475.
PubMed
2) Drobyski WR, et al.:Spontaneous regression in non-Hodgkin's lymphoma:Clinical and pathogenetic considerations. Am J Hematol 1989;31:138-141.
PubMed
P.235 掲載の参考文献
1) McKenzie CV, et al.:Splenomegaly:Pathophysiological bases and therapeutic options. Int J Biochem Cell Biol 2018;94:40-43.
PubMed
2) Pozo AL, et al.:Splenomegaly:Investigation, diagnosis and management. Blood Rev 2009;23:105-111.
PubMed
3) Motyckova G, et al.:Why does my patient have lymphadenopathy or splenomegaly? Hematol Oncol Clin North Am 2012;26:395-408, ix.
PubMed
4) McGee S:Palpation and Percussion of the Abdomen. In:Evidence-Based Physical Diagnosis, 5th ed. Elsevier, 2021:421-432.
 
5) Brown NF, et al.:Splenomegaly. Br J Hosp Med(Lond) 2011;72:M166-M169.
PubMed
6) 清田雅智:脾腫. Hospitalist 2013;1:134-138.
 
7) Thiele J, et al.:Primary myelofibrosis. In:Swerdlow SH, et al., eds.:WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. IARC, 2017:44-50.
 
8) Gangat N, et al.:Myelofibrosis biology and contemporary management. Br J Haematol 2020;191:152-170.
PubMed
9) Cervantes F, et al.:New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-2901.
 
10) Passamonti F, et al.:A dynamic prognostic model to predict survival in primary myelofibrosis:A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703-1708.
 
11) Gangat N, et al.:DIPSS plus:A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392-397.
 
12) 慢性骨髄性白血病/骨髄増殖性腫瘍. In:日本血液学会 編:造血器腫瘍診療ガイドライン2018年版補訂版. 金原出版, 2020:89-120.
 
13) Harrison C, et al.:JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-798.
PubMed
14) Verstovsek S, et al.:A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807.
PubMed
15) Vannucchi AM, et al.:A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 2015;100:1139-1145.
PubMed
16) Piris MA, et al.:Splenic marginal zone lymphoma. In:Swerdlow SH, et al., eds.:WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. IARC, 2017:223-228.
 
17) Piris MA, et al.:Splenic marginal zone lymphoma. Best Pract Res Clin Haematol 2017;30:56-64.
PubMed
18) Arcaini L, et al.:Splenic marginal zone lymphoma:From genetics to management. Blood 2016;127:2072-2081.
PubMed
P.247 掲載の参考文献
1) Traub SJ, et al.:Initial diagnosis and management of coma. Emerg Med Clin North Am 2016;34:777-793.
PubMed
2) 松本雅則, 他:血栓性血小板減少性紫斑病(TTP)診療ガイド2017. 臨血 2017;58:271-281.
 
3) Joly BS, et al.:Thrombotic thrombocytopenic purpura. Blood 2017;129:2836-2846.
PubMed
4) Chiasakul T, et al.:Clinical and laboratory diagnosis of TTP:An integrated approach. Hematology Am Soc Hematol Educ Program 2018;2018:530-538.
PubMed
5) Bendapudi PK, et al.:Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies:A cohort study. Lancet Haematol 2017;4:e157-e164.
PubMed
6) Westwood JP, et al.:Rituximab for thrombotic thrombocytopenic purpura:Benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost 2013;11:481-490.
PubMed
7) Scully M, et al.:Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019;380:335-346.
PubMed
8) Sargent JTS, et al.:Haematological emergencies managing hypercalcaemia in adults and children with haematological disorders. Br J Haematol 2010;149:465-477.
PubMed
9) Halfdanarson TR, et al.:Emergencies in hematology and oncology. Mayo Clin Proc 2017;92:609-641.
 
10) Higdon ML, et al.:Oncologic emergencies:Recognition and initial management. Am Fam Physician 2018;97:741-748.
PubMed
11) Cook LB, et al.:Revised Adult T-cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol 2019;37:677-687.
PubMed
12) Shimoyama M:Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group(1984-87). Br J Haematol 1991;79:428-437.
 
13) 成人T細胞白血病・リンパ腫. In:日本血液学会 編:造血器腫瘍診療ガイドライン2018年版補訂版. 金原出版, 2020:273-286.
 
14) Tsukasaki K, et al.:VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma:Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007;25:5458-5464.
 
15) Toyoda K, et al.:Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma(ATL) based on the ATL prognostic index:A supplementary analysis of the JCOG9801. Br J Haematol 2019;186:440-447.
PubMed
16) Ishida T, et al.:Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen:A nationwide retrospective study. Blood 2012;120:1734-1741.
PubMed
17) Yonekura K, et al.:Mogamulizumab for adult T-cell leukemia-lymphoma:A multicenter prospective observational study. Blood Adv 2020;4:5133-5145.
PubMed
18) Ishida T, et al.:Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma:Impact on allogeneic haematopoietic stem cell transplantation. Br J Haematol 2019;184:479-483.
PubMed
19) Fuji S, et al.:Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol 2016;34:3426-3433.
PubMed
20) Ishida T, et al.:Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma:ATLL-002. J Clin Oncol 2016;34:4086-4093.
PubMed
21) Grommes C, et al.:Primary CNS lymphoma. J Clin Oncol 2017;35:2410-2418.
PubMed
22) Ferreri AJM, et al.:Evolving treatments for primary central nervous system lymphoma. Am Soc Clin Oncol Educ Book 2019;39:454-466.
PubMed
23) Schmitz N, et al.:CNS International Prognostic Index:A risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2016;34:3150-3156.
 
24) Kridel R, et al.:Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol 2011;12:1258-1266.
PubMed
25) Kridel R, et al.:Diffuse large B-cell lymphoma with testicular involvement:Outcome and risk of CNS relapse in the rituximab era. Br J Haematol 2017;176:210-221.
PubMed
26) Eyre TA, et al.:Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era:A systematic review. Haematologica 2020;105:1914-1924.
 
27) Adams BD, et al.:Myeloproliferative disorders and the hyperviscosity syndrome. Hematol Oncol Clin North Am 2010;24:585-602.
PubMed
28) Stone MJ, et al.:Evidence-based focused review of management of hyperviscosity syndrome. Blood 2012;119:2205-2208.
PubMed
29) Gertz MA:Acute hyperviscosity:Syndromes and management. Blood 2018;132:1379-1385.
PubMed
P.266 掲載の参考文献
1) Durack DT, et al.:Fever of unknown origin--reexamined and redefined. Curr Clin Top Infect Dis 1991;11:35-51.
PubMed
2) Wright WF, et al.:Fever and fever of unknown origin:Review, recent advances, and lingering dogma. Open Forum Infect Dis 2020;7:ofaa132.
PubMed
3) Graber ML, et al.:Diagnostic error in internal medicine. Arch Intern Med 165:1493-1499, 2005.
 
4) Schiff GD, et al.:Diagnostic error in medicine:Analysis of 583 physician-reported errors. Arch Intern Med 2009;169:1881-1887.
 
5) Cunha BA, et al.:Fever of unknown origin:A clinical approach. Am J Med 2015;128:1138. e1-1138. e15.
 
6) Naito T, et al.:Key diagnostic characteristics of fever of unknown origin in Japanese patients:A prospective multicentre study. BMJ Open 2019;9:e032059.
PubMed
7) Carbone PP, et al.:Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860-1861.
 
8) Cheson BD, et al.:Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma:The Lugano classification. J Clin Oncol 2014;32:3059-3068.
PubMed
9) Stein H, et al.:Hodgkin lymphomas:Introduction. In:Swerdlow SH, et al., eds.:WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. IARC, 2017:424-430.
 
10) ホジキンリンパ腫. In:日本血液学会 編:造血器腫瘍診療ガイドライン2018年版補訂版. 金原出版, 2020:295-317.
 
11) Brice P, et al.:Classical Hodgkin lymphoma. Lancet 2021;398:1518-1527.
PubMed
12) Hot A, et al.:Yield of bone marrow examination in diagnosing the source of fever of unknown origin. Arch Intern Med 2009;169:2018-2023.
PubMed
13) Ben-Baruch S, et al.:Predictive parameters for a diagnostic bone marrow biopsy specimen in the work-up of fever of unknown origin. Mayo Clin Proc 2012;87:136-142.
PubMed
14) Arber DA, et al.:Acute myeloid leukaemia with recurrent genetic abnormalities. In:Swerdlow SH, et al., eds.:WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. IARC, 2017:130-149.
 
15) Ishii E, et al.:Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 2007;86:58-65.
PubMed
16) Thomas W, et al.:Haemophagocytic lymphohistiocytosis:An elusive syndrome. Clin Med(Lond) 2016;16:432-436.
PubMed
17) Atteritano M, et al.:Haemophagocytic syndrome in rheumatic patients. A systematic review. Eur Rev Med Pharmacol Sci 2012;16:1414-1424.
PubMed
18) Henter J, et al.:HLH-2004:Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124-131.
PubMed
19) Lehmberg K, et al.:Diagnostic evaluation of patients with suspected haemophagocytic lymphohistiocytosis. Br J Haematol 2013;160:275-287.
PubMed
20) Ramos-Casals M, et al.:Adult haemophagocytic syndrome. Lancet 2014;383:1503-1516.
PubMed
21) Schram AM, et al.:How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood 2015;125:2908-2914.
 
22) Shimada K, et al.:Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol 2009;10:895-902.
 
23) Ponzoni M, et al.:Definition, diagnosis, and management of intravascular large B-cell lymphoma:Proposals and perspectives from an International Consensus Meeting. J Clin Oncol 2007;25:3168-3173.
 
24) Ponzoni M, et al.:Intravascular large B-cell lymphoma:A chameleon with multiple faces and many masks. Blood 2018;132:1561-1567.
 
25) Matsue K, et al.:Diagnosis of intravascular large B cell lymphoma:Novel insights into clinicopathological features from 42 patients at a single institution over 20 years. Br J Haematol 2019;187:328-336.
 
P.279 掲載の参考文献
1) Niscola P, et al.:Pain syndromes in haematological malignancies:An overview. Hematol J 2004;5:293-303.
PubMed
2) Niscola P, et al.:Epidemiology, features and outcome of pain in patients with advanced hematological malignancies followed in a home care program:An Italian survey. Ann Hematol 2007;86:671-676.
 
3) Shaulov A, et al.:Pain in patients with newly diagnosed or relapsed acute leukemia. Support Care Cancer 2019;27:2789-2797.
PubMed
4) Loeser JD, et al.:Pain:An overview. Lancet 1999;353:1607-1609.
PubMed
5) Blumenthal DT, et al.:Neurologic manifestations of hematologic disorders. Neurol Clin 2002;20:265-281, viii.
PubMed
6) Glass J:Neurologic complications of lymphoma and leukemia. Semin Oncol 2006;33:342-347.
PubMed
7) Headache Classification Committee of the International Headache Society(IHS)著, 日本頭痛学会・国際頭痛分類委員会 訳:国際頭痛分類第3版(ICHD-3)日本語版. 2018〔Headache Classification Committee of the International Headache Society (IHS):The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1-211〕. https://www.jhsnet.net/kokusai_new_2019.html(2022年2月閲覧)
 
8) McConaghy JR, et al.:Outpatient diagnosis of acute chest pain in adults. Am Fam Physician 2013;87:177-182.
PubMed
9) Pearigen PD:Unusual causes of abdominal pain. Emerg Med Clin North Am 1996;14:593-613.
PubMed
10) Chen EH, et al.:Abdominal pain in special populations. Emerg Med Clin North Am 2011;29:449-458, x.
PubMed
11) Ebert EC, et al.:Gastrointestinal manifestations of leukemia. J Gastroenterol Hepatol 2012;27:458-463.
PubMed
12) Gorschluter M, et al.:Neutropenic enterocolitis in adults:Systematic analysis of evidence quality. Eur J Haematol 2005;75:1-13.
PubMed
13) Rodrigues FG, et al.:Neutropenic enterocolitis. World J Gastroenterol 2017;23:42-47.
PubMed
14) Reamy BV, et al.:Henoch-Schonlein purpura(IgA vasculitis):Rapid evidence review. Am Fam Physician 2020;102:229-233.
PubMed
15) Audemard-Verger A, et al.:IgA vasculitis(Henoch-Shonlein purpura) in adults:Diagnostic and therapeutic aspects. Autoimmun Rev 2015;14:579-585.
PubMed
16) 日本骨髄腫学会 編:多発性骨髄腫の診療指針, 第5版. 文光堂, 2020.
 
17) Terpos E, et al.:Myeloma bone disease:From biology findings to treatment approaches. Blood 2019;133:1534-1539.
PubMed
18) Rasch S, et al.:Multiple myeloma associated bone disease. Cancers(Basel) 2020;12:2113.
PubMed
19) 曽我部公子, 他:多発性骨髄腫に対する支持療法. 日臨 2020;78:645-652.
Medical*Online
20) Piga A:Impact of bone disease and pain in thalassemia. Hematology Am Soc Hematol Educ Program 2017;2017:272-277.
PubMed
21) Janssens AM, et al.:Bone marrow necrosis. Cancer 2000;88:1769-1780.
PubMed
22) Deucher A, et al.:How I investigate bone marrow necrosis. Int J Lab Hematol 2019;41:585-592.
 
23) Rees DC, et al.:Sickle-cell disease. Lancet 2010;376:2018-2031.
PubMed
24) Piel FB, et al.:Sickle cell disease. N Engl J Med 2017;376:1561-1573.
PubMed
25) Piel FB, et al.:Global migration and the changing distribution of sickle haemoglobin:A quantitative study of temporal trends between 1960 and 2000. Lancet Glob Health 2014;2:e80-e89.
PubMed
26) Hassell KL:Population estimates of sickle cell disease in the U. S. Am J Prev Med 2010;38:S512-S521.
 
27) Russo-Mancuso G, et al.:Survey of sickle cell disease in Italy. Haematologica 1998;83:875-881.
PubMed
28) Paul RN, et al.:Acute chest syndrome:Sickle cell disease. Eur J Haematol 2011;87:191-207.
PubMed
P.294 掲載の参考文献
1) Trayes KP, et al.:Edema:Diagnosis and management. Am Fam Physician 2013;88:102-110.
PubMed
2) Edema and Deep Vein Thrombosis. In:McGee S:Evidence-Based Physical Diagnosis, 5th ed. Elsevier, 2021:461-466.
 
3) 内山聖:浮腫の鑑別疾患・診断マニュアル. 診断と治療 2016;104:974-978.
Medical*Online
4) 穂苅量太, 他:蛋白漏出性胃腸症. 診断と治療 2016;104:1059-1063.
Medical*Online
5) van der Heide F:Acquired causes of intestinal malabsorption. Best Pract Res Clin Gastroenterol 2016;30:213-224.
PubMed
6) Ebert EC, et al.:Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol 2008;103:776-787.
PubMed
7) Rice TW, et al.:The superior vena cava syndrome:Clinical characteristics and evolving etiology. Medicine(Baltimore) 2006;85:37-42.
PubMed
8) 日本骨髄腫学会 編:多発性骨髄腫の診療指針, 第5版. 文光堂, 2020.
 
9) Dimopoulos MA, et al.:Renal impairment in patients with multiple myeloma:A consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010;28:4976-4984.
 
10) 曽我部公子, 他:多発性骨髄腫に対する支持療法. 日臨 2020;78:645-652.
Medical*Online
11) 廣田彰男:リンパ浮腫の特徴と対策. Fluid Manag Renaiss 2015;5:268-272.
Medical*Online
12) de Kerviler E, et al.:Image-guided needle biopsy for diagnosis and molecular biology in lymphomas. Best Pract Res Clin Haematol 2012;25:29-39.
PubMed
13) 河野良寛, 他:悪性リンパ腫CTガイド下生検の実際とその有用性. 日臨 2000;58:624-628.
Medical*Online
14) 濾胞性リンパ腫. In:日本血液学会 編:造血器腫瘍診療ガイドライン2018年版補訂版. 金原出版, 2020:179-189.
 
15) 古林勉:濾胞性リンパ腫の治療. 臨血 2021;62:1070-1076.
 
16) Solal-Celigny P, et al.:Follicular Lymphoma International Prognostic Index. Blood 2004;104:1258-1265.
PubMed
17) Federico M, et al.:Follicular Lymphoma International Prognostic Index 2:A new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. J Clin Oncol 2009;27:4555-4562.
PubMed
18) Chikama R, et al.:Nonepisodic angioedema associated with eosinophilia:Report of 4 cases and review of 33 young female patients reported in Japan. Dermatology 1998;197:321-325.
PubMed
19) 山内高弘, 他:好酸球性血管性浮腫. In:血液症候群-その他の血液疾患を含めて2, 第2版(別冊日本臨牀 新領域別症候群シリーズ). 日本臨牀社, 2013:152-154.
 
20) 正木康史, 他:新規疾患-TAFRO 症候群の診断基準・重症度分類・治療指針. 臨血 2016;57:2029-2037.
 
21) Masaki Y, et al.:2019 updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol 2020;111:155-158,.
PubMed
22) Igawa T, et al.:TAFRO syndrome. Hematol Oncol Clin North Am 2018;32:107-118.
PubMed
23) Dispenzieri A, et al.:Overview of Castleman disease. Blood 2020;135:1353-1364.
PubMed
24) Liu AY, et al.:Idiopathic multicentric Castleman's disease:A systematic literature review. Lancet Haematol 2016;3:163.
 
25) 吉崎和幸, 他:キャッスルマン病診療の参照ガイド. 臨血 2017;58:97-107.
 
26) 岡本真一郎:特発性多中心性キャッスルマン病の診断と治療の進歩. 臨血 2019;60:1205-1211.
 
27) Dispenzieri A:POEMS syndrome:2019 update on diagnosis, risk-stratification, and management. Am J Hematol 2019;94:812-827.
PubMed
28) 中世古知昭, 他:POEMS 症候群の診断と治療. 日臨 2020;78:658-663.
Medical*Online

Part C 健康診断からのアプローチ

P.308 掲載の参考文献
1) 矢冨裕:基準範囲と臨床判断値. 日医師会誌 2021;150:S38-S40.
 
2) 新谷和夫:自動血球計算機によるデータの読み方. 臨検 1971;15:342-347.
 
3) 折茂淳, 他:臨床検査データの個人内変動. 日総合健診医会誌 1987;4:413-420.
 
4) 日本人間ドック学会:判定区分 2021年度版, 2020. https://www.ningen-dock.jp/wp/wp-content/uploads/2013/09/2021hanteikubun.pdf(2022年2月閲覧)
 
5) 西川真子, 他:血算. medicina 2020;57:844-847.
 
6) 大田雅嗣:高齢者の貧血. 日老医誌 2011;48:20-23.
 

Part D 診断・治療後のアプローチ

P.316 掲載の参考文献
1) 宮崎仁:血液疾患患者の風邪診療. medicina 2014;51:500-503.
 
2) 骨髄異形成症候群の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ:骨髄異形成症候群診療の参照ガイド令和1年改訂版. 厚生労働科学研究費補助金 難治性疾患等政策研究事業 特発性造血障害に関する調査研究班(研究代表者 三谷絹子), 2020. http://zoketsushogaihan.umin.jp/file/2020/04v2.pdf(2022年2月閲覧)
 
3) 日本臨床腫瘍学会 編:発熱性好中球減少症(FN)診療ガイドライン-がん薬物療法時の感染対策, 改訂第2版. 南江堂, 2017.
 
4) Freifeld AG, et al.:Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer:2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56-e93.
 
5) 血液製剤の使用にあたって, 第5版. じほう, 2017.
 
6) 米村雄士, 他:科学的根拠に基づいた赤血球製剤の使用ガイドライン. 日輸血細胞治療会誌 2016;62:641-650.
Medical*Online
7) 樋口敬和:輸血すべき貧血と輸血を避けるべき貧血. 診断と治療 2019;107:591-594.
Medical*Online
8) 輸血後鉄過剰症の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ:輸血後鉄過剰症診療の参照ガイド 令和1年改訂版. 厚生労働科学研究費補助金 難治性疾患等政策研究事業 特発性造血障害に関する調査研究班(研究代表者 三谷絹子), 2020. http://zoketsushogaihan.umin.jp/file/2020/05.pdf(2022年2月閲覧)
 
9) Brittenham GM:Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011;364:146-156.
PubMed
10) 高見昭良, 他:科学的根拠に基づいた血小板製剤の使用ガイドライン-2019年改訂版. 日輸血細胞治療会誌 2019;65:544-561.
Medical*Online
11) Andres E, et al.:Oral cobalamin(vitamin B(12)) treatment. An update. Int J Lab Hematol 2009;31:1-8.
PubMed
12) Estey E, et al.:Routine bone marrow exam during first remission of acute myeloid leukemia. Blood 1996;87:3899-3902.
PubMed
13) 慢性骨髄性白血病/骨髄増殖性腫瘍. In:日本血液学会 編:造血器腫瘍診療ガイドライン2018年版補訂版. 金原出版, 2020:89-120.
 
14) Steegmann JL, et al.:European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016;30:1648-1671.
PubMed
15) Truong Q, et al.:Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission. Clin Lymphoma Myeloma Leuk 2014;14:50-55.
PubMed
16) El-Galaly TC, et al.:Role of routine imaging in detecting recurrent lymphoma:A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. Am J Hematol 2014;89:575-580.
PubMed
17) Thompson CA, et al.:Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Ann Oncol 2010;21:2262-2266.
PubMed
18) 神田善伸:同種造血幹細胞移植後(血液悪性疾患のフォローアップを依頼されたら). medicina 2010;47:2184-2190.
 
19) 日本骨髄腫学会 編:多発性骨髄腫の診療指針, 第5版. 文光堂, 2020.
 
20) リンパ形質細胞性リンパ腫/ワルデンシュトレームマクログロブリン血症. In:日本血液学会 編:造血器腫瘍診療ガイドライン2018年版補訂版. 金原出版, 2020:208-214.
 
21) 柏木浩和, 他:成人特発性血小板減少性紫斑病治療の参照ガイド2019改訂版. 臨血 2019;60:877-896.
 
22) 日笠聡, 他:von Willebrand 病の診療ガイドライン2021年版. 日血栓止血会誌 2021;32:413-481.
 
23) 藤井輝久, 他:インヒビターのない血友病患者に対する止血治療ガイドライン-2013年改訂版. 日血栓止血会誌 2013;24:619-639.
 
24) Epstein AS, et al.:Palliative care and hematologic oncology:The promise of collaboration. Blood Rev 2012;26:233-239.
PubMed
25) LeBlanc TW, et al.:When and why should patients with hematologic malignancies see a palliative care specialist? Hematology Am Soc Hematol Educ Program 2015;2015:471-478.
 
26) Odejide OO, et al.:End-of-life care for blood cancers:A series of focus groups with hematologic oncologists. J Oncol Pract 2014;10:396.
 
27) Chin-Yee N, et al.:Red blood cell transfusion in adult palliative care:A systematic review. Transfusion 2018;58:233-241.
PubMed
28) Prommer E:Management of bleeding in the terminally ill patient. Hematology 2005;10:167-175.
PubMed

書評

最近チェックした商品履歴

Loading...